Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 amlitelimab in moderate-to-severe atopic dermatitis after inadequate response to biologic or oral JAK inhibitor therapy
NL-OMON58836Phase 3Completed
- Sponsor
- Sanofi
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing amlitelimab + background topical therapy with placebo + background topical therapy (2 arms). Primary endpoints: Proportion of participants with vIGA-AD 0 or 1 and at least 2-point reduction from baseline at Week 36 and Proportion of participants reaching EASI-75 at Week 36. Started May 2024; status: completed.
02
Drugs
amlitelimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NL-OMON58836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58836.